A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

PHASE3TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

March 6, 2023

Study Completion Date

August 11, 2023

Conditions
IleusGastro-Intestinal Disorder
Interventions
DRUG

LB1148

A total of 700 mL of drug product will be administered orally as a split dose before surgery.

DRUG

Placebo

A total of 700 mL of placebo will be administered orally as a split dose before surgery.

Trial Locations (23)

10029

Site 317, New York

10032

Site 356, New York

21237

Site 321, Baltimore

27599

Site 318, Chapel Hill

32224

Site 358, Jacksonville

33136

Site 331, Miami

33756

Site 351, Clearwater

36617

Site 315, Mobile

43210

Site 313, Columbus

49503

Site 355, Grand Rapids

52242

Site 357, Iowa City

55905

Site 325, Rochester

63110

Site 352, St Louis

75390

Site 320, Dallas

77030

Site 319, Houston

84132

Site 326, Salt Lake City

90502

Site 312, Torrance

92037

Site 354, La Jolla

92123

Site 350, San Diego

92868

Site 329, Orange

06610

Site 359, Bridgeport

01805

Site 324, Burlington

02906

Site 353, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Palisade Bio

INDUSTRY

NCT05470387 - A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection | Biotech Hunter | Biotech Hunter